Evigrade
Moderate

Simvastatin × Warfarin

HMG-CoA reductase inhibitors (statins)×Vitamin K antagonist anticoagulants

Mechanism

Simvastatin weakly inhibits CYP3A4 and partly displaces warfarin from protein binding. INR may rise by 0.5–1 in the first 2 weeks.

Symptoms

Gum bleeding, epistaxis, bruising without trauma, black or tarry stools, haematuria. Higher risk in older patients, prior peptic ulcer disease, and chronic kidney disease.

Management

On simvastatin initiation, check INR at 1 and 2 weeks, then per usual schedule. If INR rises, reduce warfarin by 10%. Alternatives: pravastatin or rosuvastatin (minimal warfarin effect).

Sources

All interactions